Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 01/27 03:06:01 pm
130.7 EUR   -2.46%
01/21CARL ZEISS MEDITEC AG : DZ Bank drops its Sell rating
MD
01/20CARL ZEISS MEDITEC AG : Berenberg sticks Neutral
MD
01/20CARL ZEISS MEDITEC AG : Deutsche Bank reiterates its Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Carl Zeiss Meditec : concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic

10/29/2020 | 08:04am EST

DGAP-Ad-hoc: Carl Zeiss Meditec AG / Key word(s): Annual Results
Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic

29-Oct-2020 / 14:04 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Carl Zeiss Meditec AG concludes fiscal year 2019/20 with a recovery in profit in fourth quarter - outlook remains uncertain due to COVID-19 pandemic
Jena, October 29, 2020

Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of approximately EUR 1,335.5 million in fiscal year 2019/20 (previous year EUR 1,459.3 million) and has thereby exceeded the forecast of approx. EUR 1.3 billion provided on July 15, 2020. This corresponds to a decline of -8.5% vs. the past year. After adjustment for currency effects[1], the decline amounted to -8.7%. In the fourth quarter of 2019/20, revenue reached EUR 367.6 million (Q4 2018/19: EUR 431.7 million), a decline of -14.9%. After adjustment for currency effects, the decline amounted to around -14.5%.

Earnings before interest and taxes (EBIT)[2] amounted to EUR 177.6 million in fiscal year 2019/20 (previous year EUR 264.7 million). EBIT margin (EBIT / revenue) was 13.3% (previous year 18.1%). In the fourth quarter of 2019/20, EBIT amounted to EUR 65.7 million (Q4 2018/19: 80.5 million), EBIT margin was 17.9% (Q4 2018/19: 18.6%).

Earnings per share (EPS)[3] declined to EUR 1.37 (previous year EUR 1.79). In the fourth quarter of 2019/20, EPS was EUR 0.60 (Q4 2018/19: EUR 0.57).

Full results for fiscal year 2019/20 will be provided on Dec 11, 2020.

Carl Zeiss Meditec broadly expects a recovery of its markets in fiscal year 2020/21 and thereby a return to growth in revenue and EBIT. Due to the current trend in COVID-19 infections in Europe and North America, an additional impact from the pandemic cannot be ruled out at the outset of the new fiscal year, though. From today's point of view, the company expects revenue and EBIT for the first months of the new fiscal year 2020/21 to come in below last year's values for the same period.
 

 

Contact for investors and press
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Tel.: +49 3641 220-116
E-Mail: investors.meditec@zeiss.com

 

[1] Currency-adjusted sales growth is determined by weighing sales in the comparative period with current instead of actual historical exchange rates.
[2] Earnings before interest and taxes (also operating profit, EBIT) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated in accordance with IFRS standards (see Annual Report 2018/19, p. 76 for reconciliation).
[3] Earnings per share (also EPS) refers to a key earnings figure within the Carl Zeiss Meditec Group and is calculated according to IFRS standards (see Annual Report 2018/19, p. 76 for reconciliation).


29-Oct-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Carl Zeiss Meditec AG
Göschwitzer Str. 51-52
07745 Jena, Germany
Germany
Phone: +49 (0)3641 220-0
Fax: +49 (0)3641 220-112
E-mail: investors.meditec@zeiss.com
Internet: www.zeiss.de/meditec-ag/ir
ISIN: DE0005313704
WKN: 531370
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1144021

 
End of Announcement DGAP News Service

1144021  29-Oct-2020 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1144021&application_name=news&site_id=zonebourse_sftp

© EQS 2020
All news about CARL ZEISS MEDITEC AG
01/21CARL ZEISS MEDITEC AG : DZ Bank drops its Sell rating
MD
01/20CARL ZEISS MEDITEC AG : Berenberg sticks Neutral
MD
01/20CARL ZEISS MEDITEC AG : Deutsche Bank reiterates its Buy rating
MD
01/19CARL ZEISS MEDITEC : Ad Hoc Announcement 19-Jan-2021
PU
01/19CARL ZEISS MEDITEC : achieves increase in profit in first quarter 2020/21
EQ
01/19DGAP-ADHOC : Carl Zeiss Meditec AG achieves increase in profit in first quarter ..
DJ
01/13OPTISCAN IMAGING : Receives Orders from Carl Zeiss Meditec; Shares Fall 4%
MT
2020DGAP-RPT : Carl Zeiss Meditec AG: Release according to Article 111c (4) of the A..
EQ
2020CARL ZEISS MEDITEC AG : Reduced to Neutral by NorldLB
MD
2020CARL ZEISS MEDITEC AG : UBS sticks Neutral
MD
More news
Financials
Sales 2021 1 507 M 1 825 M 1 825 M
Net income 2021 182 M 220 M 220 M
Net cash 2021 612 M 741 M 741 M
P/E ratio 2021 66,9x
Yield 2021 0,50%
Capitalization 11 699 M 14 229 M 14 165 M
EV / Sales 2021 7,36x
EV / Sales 2022 6,60x
Nbr of Employees 3 290
Free-Float 40,9%
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | AFX | DE0005313704 | MarketScreener
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 112,25 €
Last Close Price 134,00 €
Spread / Highest target 12,7%
Spread / Average Target -16,2%
Spread / Lowest Target -55,2%
EPS Revisions
Managers and Directors
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Christian Müller Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CARL ZEISS MEDITEC AG23.05%14 577
THERMO FISHER SCIENTIFIC11.39%201 271
DANAHER CORPORATION5.33%166 214
INTUITIVE SURGICAL, INC.-5.92%90 477
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.14.55%85 238
ILLUMINA, INC.13.66%61 400